AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06655597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: REDS Powder
Description: Dietary supplement powder
Study NCT06654908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resisted exercise using sand bags,resistance machines and elastic bands
Description: Rehabilitative exercise training will be performed as previously described. All exercises will be performed using free weights, elastic bands and variable-resistance machines. Modifications to exercises will be made when appropriate depending on the patient injury characteristics. The load will be gradually increased from 50-60% of 3RM at the beginning of the program up to 80-85% of 3RM (repetitions maximum) at the end of the program. All exercise sessions will be preceded by a 5-minute warm-up at \&lt;50% VO2peak. No strength training activities will be permitted outside the supervised training session; however, both groups will be encouraged to maintain normal daily activities
Study NCT06600295 — intervention group
Intervention type: OTHER
Intervention: tests/questionnaires
Description: EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS
Study NCT05570123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets a day, one in the morning, one in the evening
Study NCT05407922 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy vs Non-laparoscopy approach
Description: Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
Study NCT06600295 — intervention group
Intervention type: BIOLOGICAL
Intervention: biological samples
Description: blood, saliva, tongue mucus
Study NCT06600295 — intervention group
Intervention type: OTHER
Intervention: evaluation
Description: strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s
Study NCT06589323 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary artery bypass graft
Description: All patients included will undergo coronary artery bypass graft surgery. During surgery, every graft will be evaluated through transit time flowmetry (TTFM) and intraoperative ultrasound control (HFUS).
Study NCT06593782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: 1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;
Study NCT06593782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolasetron
Description: 1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;
Study NCT04547153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 200mg/square metre/day civ D1-D21
Study NCT04547153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25mg/square metre ivdrip D1, D8, D15
Study NCT06592183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-phone based, self-driven speech rehabilitation
Description: Participants will perform the speech exercises for 60 min per day. Participants may complete the speech exercises all at once or split them into several sessions. Thus, participants assigned to the intervention group will use the application for 30-60 min daily, 5 days per week, for 4 consecutive weeks.
Study NCT06592131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF844
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
Study NCT06155448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perennial Malaria Chemoprevention effect
Description: Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
Study NCT04926220 — intervention group
Intervention type: DEVICE
Intervention: Trans-esophageal Doppler monitoring
Description: Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
Study NCT04926220 — intervention group
Intervention type: DEVICE
Intervention: MostCareUP Haemodynamic Monitor
Description: MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
Study NCT04926220 — intervention group
Intervention type: DEVICE
Intervention: Argos Cardiac Output (CO) Monitor
Description: Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
Study NCT06592157 — intervention group
Intervention type: OTHER
Intervention: NewEpi Plus Liquid Wound Dressing
Description: 1. Hold the spray nozzle 7-10 cm away from the wound. Apply the product evenly over the wound, with a dosage of one spray (0.1 ml) per 10x10 cm² of wound area.~2. Wait for 2 minutes. It is not necessary to wait until the solution is completely dry; you can proceed with applying ointments and various types of dressings as directed by the physician.~3. Use once a day for 21 days. The frequency of use can be adjusted according to the physician\&#39;s instructions.
Study NCT06592157 — intervention group
Intervention type: OTHER
Intervention: standard wound care
Description: The standard wound care protocol aims to provide comprehensive and systematic care for patients to ensure smooth healing of surgical wounds. These care measures include regular cleaning, disinfection, dressing changes, and continuous observation and assessment of the wound condition. Through strict aseptic techniques and scientific care procedures, standard wound care effectively reduces the risk of infection and promotes wound healing.
Study NCT06588985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Coaching Parent Training Workshop
Description: Parents will attend a 3-hour online workshop that introduces the fundamentals of emotion coaching and the phone consultations will be used to help parents troubleshoot and brainstorm application of the workshop content.
Study NCT06588985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Parents will only receive the parent workshop and phone consultations after they have completed all the required questionnaires.
Study NCT06601153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT
Description: Cardiac CT to characterize coronary atherosclerosis
Study NCT06591871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management educational program for post mastectomy lymphedema women
Description: The researcher created this program in response to the identified needs of post mastectomy lymphedema women to provide them with essential knowledge and self-care practices concerning post-mastectomy lymphedema. It was designed as a straightforward Arabic booklet written in simple language and supplemented with colorful illustrations and images to accommodate women of varying educational levels. It was consisted of two sections:~Theoretical section included the following (A brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors , stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care ,a healthy nutrition and when you call your physician ).~Practical section included (use of compression bandages, garments and their care, upper extremity lymphedema exercises, Manual Lymphatic Drainage (MLD) massage).
Study NCT06591793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVB-081
Description: Single subretinal administration
Study NCT05199194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Intravenous thrombolysis with tenecteplase 0.25mg/kg
Study NCT05199194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
Study NCT05733351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO
Study NCT05733351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study NCT05417633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)
Description: Inducing different values of monovision
Study NCT05733351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05733351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05733351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT05733351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT05733351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET
Study NCT05733351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05733351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET
Study NCT05733351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vudalimab
Description: Given IV
Study NCT06596434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: 4-Aminopyridine
Description: Active study drug
Study NCT06596434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT06596707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconomer
Description: zirconia modified glass ionomer
Study NCT06596707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid composite
Description: conventional composite
Study NCT06586983 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg po OD
Study NCT06600945 — intervention group
Intervention type: OTHER
Intervention: Cataract surgery
Description: With local anesthetic in peribulbar anesthesia
Study NCT06594432 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: R-CHOP+Z+MTX
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Study NCT06594432 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: R-CHOP+MTX
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Study NCT06603896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy and placebo patches will be used
Study NCT06603896 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy and placebo patches will be used
Study NCT06543199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local application of hyaluronic acid agent to the wound site
Description: Evaluation of the effect of local use of hyaluronic acid agent on wound healing
Study NCT06543199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local application of hypericum perforatum L to the wound site
Description: Hyperıcum perforatum L ajanının lokal kullanımının yara iyileşmesine etkisinin değerlendirilmesi
Study NCT06543199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound healing monitoring
Description: Doctor visit on days 3, 7, 14, 21 and 28
Study NCT06590298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
Description: The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
Study NCT06592599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.
Study NCT06592599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation
Description: Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows:~Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.~Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows:~Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution.~Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation.
Study NCT06601049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ResArgin
Description: Resveratrol-based supplement
Study NCT06601049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ResArgin
Description: Resveratrol-based supplement
Study NCT06325813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive TMS
Description: In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. Both iTBS trains will be active stimulation using the active TMS coil.
Study NCT06325813 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive TMS
Description: In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. The first iTBS train will be sham stimulation using the sham TMS coil. The second iTBS train will be active stimulation using the active TMS coil.
Study NCT05650736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
Study NCT05286749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Workshop plus Clinician-Collected Cervical Swab
Description: clinician-collection methods using speculum and cervical swabs
Study NCT05286749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Workshop plus Participant-Collected Cervical Swab
Description: Evalyn® Brush (Rovers® Medical Devices, Netherlands)
Study NCT05286749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV testing on Participant-Collected Cervical Swab Samples
Description: Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
Study NCT04942834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone
Description: Class I or III antiarrhythmic drug, including sotalol
Study NCT04942834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation
Description: Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
Study NCT04951947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS201 combine with Lenvatinib
Description: JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
Study NCT04336553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social prescribing in Sweden (SPiS)
Description: Social prescribing in sweden (SPiS)
Study NCT05987930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone lid technique
Description: group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex
Study NCT05987930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard technique
Description: group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
Study NCT05447780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery
Study NCT04664686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF catheter ablation
Description: Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
Study NCT04664686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV node ablation
Description: AV node ablation
Study NCT06128954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 900mg TETA 4HCl Once Daily Formulation
Description: 3x300mg trientine base tablets as a single AM dose
Study NCT06128954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 900mg TETA 4HCl Cuprior®
Description: 6 x150mg trientine base tablets in two equally divided doses
Study NCT06207591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG (electrocorticography) sensing
Description: Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
Study NCT04590521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil®, Merck
Description: Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
Study NCT05199077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-XANTHO
Description: a topical applied ointment
Study NCT05199077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GM-XANTHO
Description: a topical applied ointment
Study NCT05128916 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intralesional platelet rich plasma
Description: Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
Study NCT05128916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral terbinafine
Description: Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
Study NCT05142137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinkable solution
Description: The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
Study NCT05142137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drinkable solution
Description: The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
Study NCT06375967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study NCT06375967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study NCT06375967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm, 8x8mm. Consider 10x10mm or 10x15mm if abundant pathological material in gallblader.~* DPPS size: 7Fr x 3-5-7cm.